Search

Your search keyword '"Jouret-Mourin, A"' showing total 589 results
Start Over Author "Jouret-Mourin, A"
589 results on '"Jouret-Mourin, A"'

1. Diagnostic Pitfall of Gastric Signet-Ring Cells: How to Diagnose a Benign Signet-Ring Cell From a Malignant One.

Author

Van Der Pluijm, C., Deprez, P., Libbrecht, L., Jouret-Mourin, A., and Dano, H.

Subjects
ENDOSCOPIC surgery, STOMACH cancer, CELLULAR recognition, EPITHELIAL cells, CADHERINS, GASTRIC mucosa
Abstract

Sometimes non-neoplastic changes of the gastric mucosa mimic diffuse-type gastric carcinoma, specifically signet-ring cell adenocarcinoma. In fact, gastric epithelial cells undergoing signet-ring cell change have a cellular morphology that is almost identical to signet-ring cell adenocarcinoma, often leading to misdiagnosis. Accurate recognition of signet-ring cell change is essential to avoid overdiagnosis and overtreatment of signet-ring cell adenocarcinoma. Research on this topic is limited and clinicians lack formal diagnostic tools when signet-ring cells are detected in biopsy specimens. The aims of this study are 3-fold. Firstly, to increase the awareness of both clinicians and pathologists of this rare but highly significant entity. Secondly, to report 4 additional examples of signet-ring cell change and analyze them alongside signet-ring cell adenocarcinoma to compare their morphological and phenotypic features and their evolution over time. Finally, to highlight the potential utility of endoscopic resection to confirm the diagnosis. Cells in signet-ring cell change strongly express E-cadherin, show a wild-type p53 expression, and have a low Ki67 index. In contrast, cells in signet-ring cell adenocarcinoma strongly express p53, have high proliferation rates, and show either no or weak E-cadherin staining. Genetic analysis may be useful in identifying patients at risk of hereditary early diffuse gastric adenocarcinoma, which can mimic signet-ring cell change. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Inflammatory Bowel Diseases

Author

Geboes, Karel, Dewit, Olivier, Moreels, Tom G., Faa, Gavino, Jouret-Mourin, Anne, Jouret-Mourin, Anne, editor, Faa, Gavino, editor, and Geboes, Karel, editor

Published
2018
Full Text
View/download PDF

5. Infectious Colitis

Author

Dano, Helene, Dewit, Olivier, Jouret-Mourin, Anne, Jouret-Mourin, Anne, editor, Faa, Gavino, editor, and Geboes, Karel, editor

Published
2018
Full Text
View/download PDF

7. Ileitis

Author

Geboes, Karel, Jouret-Mourin, Anne, Jouret-Mourin, Anne, editor, Faa, Gavino, editor, and Geboes, Karel, editor

Published
2018
Full Text
View/download PDF

9. Eosinophilic Colitis

Author

Jouret-Mourin, Anne, Geboes, Karel, Jouret-Mourin, Anne, editor, Faa, Gavino, editor, and Geboes, Karel, editor

Published
2018
Full Text
View/download PDF

11. Drug-Induced Colon Injury

Author

Libbrecht, Louis, Jouret-Mourin, Anne, Geboes, Karel, Jouret-Mourin, Anne, editor, Faa, Gavino, editor, and Geboes, Karel, editor

Published
2018
Full Text
View/download PDF

14. Introduction

Author

Jouret-Mourin, Anne, Geboes, Karel, Faa, Gavino, Jouret-Mourin, Anne, editor, Faa, Gavino, editor, and Geboes, Karel, editor

Published
2018
Full Text
View/download PDF

16. Evolution of Metastases in Space and Time under Immune Selection

Author

Angelova, Mihaela, Mlecnik, Bernhard, Vasaturo, Angela, Bindea, Gabriela, Fredriksen, Tessa, Lafontaine, Lucie, Buttard, Bénédicte, Morgand, Erwan, Bruni, Daniela, Jouret-Mourin, Anne, Hubert, Catherine, Kartheuser, Alex, Humblet, Yves, Ceccarelli, Michele, Syed, Najeeb, Marincola, Francesco M., Bedognetti, Davide, Van den Eynde, Marc, and Galon, Jérôme

Published
2018
Full Text
View/download PDF

17. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Author

Pagès, Franck, Mlecnik, Bernhard, Marliot, Florence, Bindea, Gabriela, Ou, Fang-Shu, Bifulco, Carlo, Lugli, Alessandro, Zlobec, Inti, Rau, Tilman T, Berger, Martin D, Nagtegaal, Iris D, Vink-Börger, Elisa, Hartmann, Arndt, Geppert, Carol, Kolwelter, Julie, Merkel, Susanne, Grützmann, Robert, Van den Eynde, Marc, Jouret-Mourin, Anne, Kartheuser, Alex, Léonard, Daniel, Remue, Christophe, Wang, Julia Y, Bavi, Prashant, Roehrl, Michael H A, Ohashi, Pamela S, Nguyen, Linh T, Han, SeongJun, MacGregor, Heather L, Hafezi-Bakhtiari, Sara, Wouters, Bradly G, Masucci, Giuseppe V, Andersson, Emilia K, Zavadova, Eva, Vocka, Michal, Spacek, Jan, Petruzelka, Lubos, Konopasek, Bohuslav, Dundr, Pavel, Skalova, Helena, Nemejcova, Kristyna, Botti, Gerardo, Tatangelo, Fabiana, Delrio, Paolo, Ciliberto, Gennaro, Maio, Michele, Laghi, Luigi, Grizzi, Fabio, Fredriksen, Tessa, Buttard, Bénédicte, Angelova, Mihaela, Vasaturo, Angela, Maby, Pauline, Church, Sarah E, Angell, Helen K, Lafontaine, Lucie, Bruni, Daniela, El Sissy, Carine, Haicheur, Nacilla, Kirilovsky, Amos, Berger, Anne, Lagorce, Christine, Meyers, Jeffrey P, Paustian, Christopher, Feng, Zipei, Ballesteros-Merino, Carmen, Dijkstra, Jeroen, van de Water, Carlijn, van Lent-van Vliet, Shannon, Knijn, Nikki, Mușină, Ana-Maria, Scripcariu, Dragos-Viorel, Popivanova, Boryana, Xu, Mingli, Fujita, Tomonobu, Hazama, Shoichi, Suzuki, Nobuaki, Nagano, Hiroaki, Okuno, Kiyotaka, Torigoe, Toshihiko, Sato, Noriyuki, Furuhata, Tomohisa, Takemasa, Ichiro, Itoh, Kyogo, Patel, Prabhu S, Vora, Hemangini H, Shah, Birva, Patel, Jayendrakumar B, Rajvik, Kruti N, Pandya, Shashank J, Shukla, Shilin N, Wang, Yili, Zhang, Guanjun, Kawakami, Yutaka, Marincola, Francesco M, Ascierto, Paolo A, Sargent, Daniel J, Fox, Bernard A, and Galon, Jérôme

Published
2018
Full Text
View/download PDF

18. Infectious Colitis

Author

Jouret-Mourin, Anne, van Krieken, J. H. J. M., Series Editor, Carneiro, Fátima, editor, Chaves, Paula, editor, and Ensari, Arzu, editor

Published
2017
Full Text
View/download PDF

19. Campylobacter Enterocolitis

Author

Jouret-Mourin, Anne, van Krieken, J. H. J. M., Series Editor, Carneiro, Fátima, editor, Chaves, Paula, editor, and Ensari, Arzu, editor

Published
2017
Full Text
View/download PDF

20. Bacterial Enterocolitis

Author

Jouret-Mourin, Anne, van Krieken, J. H. J. M., Series Editor, Carneiro, Fátima, editor, Chaves, Paula, editor, and Ensari, Arzu, editor

Published
2017
Full Text
View/download PDF

21. Salmonellosis

Author

Jouret-Mourin, Anne, van Krieken, J. H. J. M., Series Editor, Carneiro, Fátima, editor, Chaves, Paula, editor, and Ensari, Arzu, editor

Published
2017
Full Text
View/download PDF

22. Supplementary Figures from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Author

El Sissy, Carine, primary, Kirilovsky, Amos, primary, Van den Eynde, Marc, primary, Muşină, Ana-Maria, primary, Anitei, Maria-Gabriela, primary, Romero, Alfredo, primary, Marliot, Florence, primary, Junca, Audelaure, primary, Doyen, Jérôme, primary, Mlecnik, Bernhard, primary, Haicheur, Nacilla, primary, Fredriksen, Tessa, primary, Lagorce, Christine, primary, Jouret-Mourin, Anne, primary, Leonard, Daniel, primary, Bibeau, Frédéric, primary, Iseas, Soledad, primary, Roca, Enrique L., primary, Cabanne, Ana M., primary, Vaccaro, Carlos A., primary, Santino, Juan P., primary, Huertas, Eduardo, primary, Tougeron, David, primary, Carvalho, Carlos, primary, Figueiredo, Nuno, primary, Perez, Rodrigo O., primary, Habr-Gama, Angelita, primary, Scripcariu, Viorel, primary, Gerard, Jean-Pierre, primary, Galon, Jérôme, primary, Zeitoun, Guy, primary, and Pagès, Franck, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Tables from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Author

El Sissy, Carine, primary, Kirilovsky, Amos, primary, Van den Eynde, Marc, primary, Muşină, Ana-Maria, primary, Anitei, Maria-Gabriela, primary, Romero, Alfredo, primary, Marliot, Florence, primary, Junca, Audelaure, primary, Doyen, Jérôme, primary, Mlecnik, Bernhard, primary, Haicheur, Nacilla, primary, Fredriksen, Tessa, primary, Lagorce, Christine, primary, Jouret-Mourin, Anne, primary, Leonard, Daniel, primary, Bibeau, Frédéric, primary, Iseas, Soledad, primary, Roca, Enrique L., primary, Cabanne, Ana M., primary, Vaccaro, Carlos A., primary, Santino, Juan P., primary, Huertas, Eduardo, primary, Tougeron, David, primary, Carvalho, Carlos, primary, Figueiredo, Nuno, primary, Perez, Rodrigo O., primary, Habr-Gama, Angelita, primary, Scripcariu, Viorel, primary, Gerard, Jean-Pierre, primary, Galon, Jérôme, primary, Zeitoun, Guy, primary, and Pagès, Franck, primary

Published
2023
Full Text
View/download PDF

24. Data from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Author

Franck Pagès, Guy Zeitoun, Jérôme Galon, Jean-Pierre Gerard, Viorel Scripcariu, Angelita Habr-Gama, Rodrigo O. Perez, Nuno Figueiredo, Carlos Carvalho, David Tougeron, Eduardo Huertas, Juan P. Santino, Carlos A. Vaccaro, Ana M. Cabanne, Enrique L. Roca, Soledad Iseas, Frédéric Bibeau, Daniel Leonard, Anne Jouret-Mourin, Christine Lagorce, Tessa Fredriksen, Nacilla Haicheur, Bernhard Mlecnik, Jérôme Doyen, Audelaure Junca, Florence Marliot, Alfredo Romero, Maria-Gabriela Anitei, Ana-Maria Muşină, Marc Van den Eynde, Amos Kirilovsky, and Carine El Sissy

Abstract

Purpose:No biomarker to personalize treatment in locally advanced rectal cancer (LARC) is currently available. We assessed in LARC whether a diagnostic biopsy-adapted immunoscore (ISB) could predict response to neoadjuvant treatment (nT) and better define patients eligible to an organ preservation strategy (“Watch-and-Wait”).Experimental Design:Biopsies from two independent cohorts (n1 = 131, n2 = 118) of patients with LARC treated with nT followed by radical surgery were immunostained for CD3+ and CD8+ T cells and quantified by digital pathology to determine ISB. The expression of immune-related genes post-nT was investigated (n = 64 patients). Results were correlated with response to nT and disease-free survival (DFS). The ISB prognostic performance was further assessed in a multicentric cohort (n = 73 patients) treated by Watch-and-Wait.Results:ISB positively correlated with the degree of histologic response (P < 0.001) and gene expression levels for Th1 orientation and cytotoxic immune response, post-nT (P = 0.006). ISB high identified patients at lower risk of relapse or death compared with ISB low [HR, 0.21; 95% confidence interval (CI), 0.06–0.78; P = 0.009]. Prognostic performance of ISB for DFS was confirmed in a validation cohort. ISB was an independent parameter, more informative than pre- (P < 0.001) and post-nT (P < 0.05) imaging to predict DFS. ISB combined with imaging post-nT discriminated very good responders that could benefit from organ preservation strategy. In the “Watch-and-Wait” cohort (n = 73), no relapse was observed in patients with ISB high (23.3%).Conclusions:ISB predicts response to nT and survival in patients with LARC treated by surgery. Its usefulness in the selection of patients eligible for a Watch-and-Wait strategy is strongly suggested.

Published
2023
Full Text
View/download PDF

25. Supplementary Figures from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Author

Franck Pagès, Guy Zeitoun, Jérôme Galon, Jean-Pierre Gerard, Viorel Scripcariu, Angelita Habr-Gama, Rodrigo O. Perez, Nuno Figueiredo, Carlos Carvalho, David Tougeron, Eduardo Huertas, Juan P. Santino, Carlos A. Vaccaro, Ana M. Cabanne, Enrique L. Roca, Soledad Iseas, Frédéric Bibeau, Daniel Leonard, Anne Jouret-Mourin, Christine Lagorce, Tessa Fredriksen, Nacilla Haicheur, Bernhard Mlecnik, Jérôme Doyen, Audelaure Junca, Florence Marliot, Alfredo Romero, Maria-Gabriela Anitei, Ana-Maria Muşină, Marc Van den Eynde, Amos Kirilovsky, and Carine El Sissy

Abstract

Supplementary Figures

Published
2023
Full Text
View/download PDF

26. Supplementary Tables from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Author

Franck Pagès, Guy Zeitoun, Jérôme Galon, Jean-Pierre Gerard, Viorel Scripcariu, Angelita Habr-Gama, Rodrigo O. Perez, Nuno Figueiredo, Carlos Carvalho, David Tougeron, Eduardo Huertas, Juan P. Santino, Carlos A. Vaccaro, Ana M. Cabanne, Enrique L. Roca, Soledad Iseas, Frédéric Bibeau, Daniel Leonard, Anne Jouret-Mourin, Christine Lagorce, Tessa Fredriksen, Nacilla Haicheur, Bernhard Mlecnik, Jérôme Doyen, Audelaure Junca, Florence Marliot, Alfredo Romero, Maria-Gabriela Anitei, Ana-Maria Muşină, Marc Van den Eynde, Amos Kirilovsky, and Carine El Sissy

Abstract

Supplementary Tables

Published
2023
Full Text
View/download PDF

27. ESD versus EMR in non-ampullary superficial duodenal tumors: a systematic review and meta-analysis

Author

Enrique Pérez-Cuadrado-Robles, Lucille Quénéhervé, Walter Margos, Tom G. Moreels, Ralph Yeung, Hubert Piessevaux, Emmanuel Coron, Anne Jouret-Mourin, and Pierre H. Deprez

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background and study aims Endoscopic submucosal dissection (ESD) has been developed as an option for treatment of esophageal, gastric and colorectal lesions. However, there is no consensus on the role of ESD in duodenal tumors. Methods This systematic review and meta-analysis compared ESD and endoscopic mucosal resection (EMR) in sporadic non-ampullary superficial duodenal tumors (NASDTs), including local experience. We conducted a search in PubMed, Scopus and the Cochrane library up to August 2017 to identify studies that compared both techniques reporting at least one main outcome (en-bloc/complete resection, local recurrence). Pooled outcomes were calculated under fixed and random-effect models. Subgroup analyses were conducted. Results A total of 753 patients presenting with 784 NASDTs (242 ESD, 542 EMR) in 14 studies were included. Tumor size (MD: 5.88, [CI95 %: 2.15, 9.62], P = 0.002, I2 = 79 %) and procedure time (MD: 65.65, [CI95 %: 40.39, 90.92], P

Published
2018
Full Text
View/download PDF

28. Comparative analysis of ESD versus EMR in a large European series of non-ampullary superficial duodenal tumors

Author

Enrique Pérez-Cuadrado-Robles, Lucille Quénéhervé, Walter Margos, Leila Shaza, Hrvoje Ivekovic, Tom G. Moreels, Ralph Yeung, Hubert Piessevaux, Emmanuel Coron, Anne Jouret-Mourin, and Pierre H. Deprez

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background and study aims The choice of endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) in non-ampullary superficial duodenal tumors (NASDTs) is challenging and the benefits of ESD remain unclear. The aim was to comparatively analyze the feasibility, outcomes and safety of these techniques in these lesions. Patients and methods This is an observational and retrospective study. All consecutive patients presenting with NASDTs who underwent EMR or ESD between 2005 and 2017 were included. The following main outcomes were comparatively evaluated: en-bloc and complete (R0) resection rates, and local recurrence. Secondary outcomes were perforation and delayed bleeding. Results One hundred sixty-six tumors in 150 patients (age: 66 years, range: 31 – 83, 42.7 % males) were resected by ESD (n = 37) or EMR (n = 129) and included. The median procedure time (81 vs. 50 min, P = 0.007) and tumor size (25 vs. 20 mm, P = 0.01) were higher in the ESD group. The global malignancy rate was 50.3 %. There were no differences in en-bloc resection (29.7 % vs. 44.2 %, P = 0.115), complete resection (19.4 % vs. 35.5 %, P = 0.069), and local recurrence (14.7 % vs. 16.7 %, P = 0.788) rates. Tumor size was associated with recurrence (28 vs. 20 mm, P = 0.008), with a median follow-up of 6.5 months. Focal recurrence (n = 22, 13.3 %) was treated endoscopically in 86.4 %. En-bloc resection in the ESD group was comparable in large ( ≥ 20 mm) and small lesions (27.6 % vs. 37.5 %, P = 0.587), while this outcome decreased significantly in large lesions resected by EMR (17.4 % vs. 75 %, P

Published
2018
Full Text
View/download PDF

29. Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer

Author

Mlecnik, Bernhard, primary, Lugli, Alessandro, additional, Bindea, Gabriela, additional, Marliot, Florence, additional, Bifulco, Carlo, additional, Lee, Jiun-Kae Jack, additional, Zlobec, Inti, additional, Rau, Tilman T., additional, Berger, Martin D., additional, Nagtegaal, Iris D., additional, Vink-Börger, Elisa, additional, Hartmann, Arndt, additional, Geppert, Carol I., additional, Kolwelter, Julie, additional, Merkel, Susanne, additional, Grützmann, Robert, additional, Van den Eynde, Marc, additional, Jouret-Mourin, Anne, additional, Kartheuser, Alex, additional, Léonard, Daniel, additional, Remue, Christophe, additional, Wang, Julia, additional, Bavi, Prashant, additional, Roehrl, Michael H. A., additional, Ohashi, Pamela S., additional, Nguyen, Linh T., additional, Han, SeongJun, additional, MacGregor, Heather L., additional, Hafezi-Bakhtiari, Sara, additional, Wouters, Bradly G., additional, Masucci, Giuseppe V., additional, Andersson, Emilia K., additional, Zavadova, Eva, additional, Vocka, Michal, additional, Spacek, Jan, additional, Petruzelka, Lubos, additional, Konopasek, Bohuslav, additional, Dundr, Pavel, additional, Skalova, Helena, additional, Nemejcova, Kristyna, additional, Botti, Gerardo, additional, Tatangelo, Fabiana, additional, Delrio, Paolo, additional, Ciliberto, Gennaro, additional, Maio, Michele, additional, Laghi, Luigi, additional, Grizzi, Fabio, additional, Fredriksen, Tessa, additional, Buttard, Bénédicte, additional, Lafontaine, Lucie, additional, Maby, Pauline, additional, Majdi, Amine, additional, Hijazi, Assia, additional, El Sissy, Carine, additional, Kirilovsky, Amos, additional, Berger, Anne, additional, Lagorce, Christine, additional, Paustian, Christopher, additional, Ballesteros-Merino, Carmen, additional, Dijkstra, Jeroen, additional, van de Water, Carlijn, additional, Vliet, Shannon van Lent-van, additional, Knijn, Nikki, additional, Mușină, Ana-Maria, additional, Scripcariu, Dragos-Viorel, additional, Popivanova, Boryana, additional, Xu, Mingli, additional, Fujita, Tomonobu, additional, Hazama, Shoichi, additional, Suzuki, Nobuaki, additional, Nagano, Hiroaki, additional, Okuno, Kiyotaka, additional, Torigoe, Toshihiko, additional, Sato, Noriyuki, additional, Furuhata, Tomohisa, additional, Takemasa, Ichiro, additional, Patel, Prabhu, additional, Vora, Hemangini H., additional, Shah, Birva, additional, Patel, Jayendrakumar B., additional, Rajvik, Kruti N., additional, Pandya, Shashank J., additional, Shukla, Shilin N., additional, Wang, Yili, additional, Zhang, Guanjun, additional, Kawakami, Yutaka, additional, Marincola, Francesco M., additional, Ascierto, Paolo A., additional, Fox, Bernard A., additional, Pagès, Franck, additional, and Galon, Jérôme, additional

Published
2023
Full Text
View/download PDF

32. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study

Author

Mlecnik, Bernhard, primary, Torigoe, Toshihiko, additional, Bindea, Gabriela, additional, Popivanova, Boryana, additional, Xu, Mingli, additional, Fujita, Tomonobu, additional, Hazama, Shoichi, additional, Suzuki, Nobuaki, additional, Nagano, Hiroaki, additional, Okuno, Kiyotaka, additional, Hirohashi, Yoshihiko, additional, Furuhata, Tomohisa, additional, Takemasa, Ichiro, additional, Patel, Prabhudas, additional, Vora, Hemangini, additional, Shah, Birva, additional, Patel, Jayendrakumar B., additional, Rajvik, Kruti N., additional, Pandya, Shashank J., additional, Shukla, Shilin N., additional, Wang, Yili, additional, Zhang, Guanjun, additional, Yoshino, Takayuki, additional, Taniguchi, Hiroya, additional, Bifulco, Carlo, additional, Lugli, Alessandro, additional, Lee, Jiun-Kae Jack, additional, Zlobec, Inti, additional, Rau, Tilman T., additional, Berger, Martin D., additional, Nagtegaal, Iris D., additional, Vink-Börger, Elisa, additional, Hartmann, Arndt, additional, Geppert, Carol I., additional, Kolwelter, Julie, additional, Merkel, Susanne, additional, Grützmann, Robert, additional, Van den Eynde, Marc, additional, Jouret-Mourin, Anne, additional, Kartheuser, Alex, additional, Léonard, Daniel, additional, Remue, Christophe, additional, Wang, Julia, additional, Bavi, Prashant, additional, Roehrl, Michael H. A., additional, Ohashi, Pamela S., additional, Nguyen, Linh T., additional, Han, SeongJun, additional, MacGregor, Heather L., additional, Hafezi-Bakhtiari, Sara, additional, Wouters, Bradly G., additional, Masucci, Giuseppe V., additional, Andersson, Emilia, additional, Zavadova, Eva, additional, Vocka, Michal, additional, Spacek, Jan, additional, Petruzelka, Lubos, additional, Konopasek, Bohuslav, additional, Dundr, Pavel, additional, Skalova, Helena, additional, Nemejcova, Kristyna, additional, Botti, Gerardo, additional, Tatangelo, Fabiana, additional, Delrio, Paolo, additional, Ciliberto, Gennaro, additional, Maio, Michele, additional, Laghi, Luigi, additional, Grizzi, Fabio, additional, Marliot, Florence, additional, Fredriksen, Tessa, additional, Buttard, Bénédicte, additional, Lafontaine, Lucie, additional, Maby, Pauline, additional, Majdi, Amine, additional, Hijazi, Assia, additional, El Sissy, Carine, additional, Kirilovsky, Amos, additional, Berger, Anne, additional, Lagorce, Christine, additional, Paustian, Christopher, additional, Ballesteros-Merino, Carmen, additional, Dijkstra, Jeroen, additional, Van de Water, Carlijn, additional, van Lent-van Vliet, Shannon, additional, Knijn, Nikki, additional, Mușină, Ana-Maria, additional, Scripcariu, Dragos-Viorel, additional, Marincola, Francesco M., additional, Ascierto, Paolo A., additional, Fox, Bernard A., additional, Pagès, Franck, additional, Kawakami, Yutaka, additional, and Galon, Jérôme, additional

Published
2022
Full Text
View/download PDF

36. Homogeneity of pathological response (PR) and histopathological growth pattern (HGP) in resected colorectal liver metastases (CRLM) are associated with favorable survival outcome after surgery.

Author

Baldin, Pamela, primary, Beniuga, Gabriella, additional, Carrasco, Javier, additional, De Cuyper, Astrid, additional, Sinapi, Isabelle, additional, Hubert, Catherine, additional, Navez, Benoit, additional, Castella, Marie-Laure, additional, Van Maanen, Aline, additional, Mlecnik, Bernhard, additional, Galon, Jerome, additional, Jouret-Mourin, Anne, additional, and Van Den Eynde, Marc, additional

Published
2022
Full Text
View/download PDF

37. Prognostic assessment of resected colorectal liver metastases integrating pathological features,<scp>RAS</scp>mutation and Immunoscore

Author

Marc Van den Eynde, Bernhard Mlecnik, Lucie Lafontaine, Franck Pages, Javier Carrasco, Gabriela Bindea, Nicolas Huyghe, Catherine Hubert, Anne Jouret-Mourin, Jérôme Galon, Nacilla Haicheur, F. Marliot, G. Beniuga, Benoit Navez, Mina Komuta, Tessa Fredriksen, Nicolas Lanthier, Pamela Baldin, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'anatomie pathologique, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, and UCL - (SLuc) Service de chirurgie et transplantation abdominale

Subjects
Male, Surgical margin, Multivariate analysis, Colorectal cancer, Gastroenterology, Metastasis, Risk Factors, Tumor Microenvironment, Aged, 80 and over, biology, Liver Neoplasms, Hazard ratio, Middle Aged, histopathological growth pattern, Phenotype, Treatment Outcome, colorectal liver metastases, Female, Original Article, Colorectal Neoplasms, tumor regression grading, chemotherapy related liver injury, Adult, medicine.medical_specialty, Immunoscore, steatohepatitis, colorectal cancer, Risk Assessment, Decision Support Techniques, Pathology and Forensic Medicine, pathological score, Predictive Value of Tests, Internal medicine, Biomarkers, Tumor, medicine, tumor microenvironment, Hepatectomy, Humans, Genetic Predisposition to Disease, Pathological, Aged, Retrospective Studies, business.industry, Metastasectomy, Original Articles, medicine.disease, Transthyretin, Genes, ras, Mutation, biology.protein, Steatohepatitis, business
Abstract

Surgical resection of colorectal liver metastases combined with systemic treatment aims to maximize patient survival. However, recurrence rates are very high postsurgery. In order to assess patient prognosis after metastasis resection, we evaluated the main patho‐molecular and immune parameters of all surgical specimens. Two hundred twenty‐one patients who underwent, after different preoperative treatment, curative resection of 582 metastases were analyzed. Clinicopathological parameters, RAS tumor mutation, and the consensus Immunoscore (I) were assessed for all patients. Overall survival (OS) and time to relapse (TTR) were estimated using the Kaplan–Meier method and compared by log‐rank tests. Cox proportional hazard models were used for uni‐ and multivariate analysis. Immunoscore and clinicopathological parameters (number of metastases, surgical margin, histopathological growth pattern, and steatohepatitis) were associated with relapse in multivariate analysis. Overall, pathological score (PS) that combines relevant clinicopathological factors for relapse, and I, were prognostic for TTR (2‐year TTR rate PS 0–1: 49.8.% (95% CI: 42.2–58.8) versus PS 2–4: 20.9% (95% CI: 13.4–32.8), hazard ratio (HR) = 2.54 (95% CI: 1.82–3.53), p

Published
2020
Full Text
View/download PDF

38. Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)

Author

UCL - (MGD) Service d'anatomie pathologique, UCL - (MGD) Service d'oncologie médicale, UCL - SSS/IREC/MORF - Pôle de Morphologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Baldin, Pamela, Carrasco, Javier, Beniuga, Gabriela, Jouret-Mourin, Anne, Demolin, Gauthier, Roland, Sandrine, D'Hondt, Lionel, Vergauwe, Philippe, Van Daele, Daniel, Mailleux, Marie, Sinapi, Isabelle, De Cuyper, Astrid, Blétard, Noëlla, Massart, Brigitte, Delos, Monique, Castella, Marie-Laure, van Maanen, Aline, Van den Eynde, Marc, UCL - (MGD) Service d'anatomie pathologique, UCL - (MGD) Service d'oncologie médicale, UCL - SSS/IREC/MORF - Pôle de Morphologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Baldin, Pamela, Carrasco, Javier, Beniuga, Gabriela, Jouret-Mourin, Anne, Demolin, Gauthier, Roland, Sandrine, D'Hondt, Lionel, Vergauwe, Philippe, Van Daele, Daniel, Mailleux, Marie, Sinapi, Isabelle, De Cuyper, Astrid, Blétard, Noëlla, Massart, Brigitte, Delos, Monique, Castella, Marie-Laure, van Maanen, Aline, and Van den Eynde, Marc

Abstract

Retrospective studies reported that preoperative oxaliplatin-based chemotherapy increased pathological response (PR) in patients resected for colorectal liver metastases (CRLM). This multicenter prospective randomized (1/1) phase II trial evaluated PR on resected CRLM after preoperative mFOLFOX6 (arm A) or FOLFIRI (arm B) + bevacizumab. The primary endpoint was the major pathological response rate (MPRR), defined as the percentage of patients presenting CRLMs with mean tumor regression grade (TRG) < 3. Secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). Out of 65 patients, 57 patients (28 and 29 in arm A/B) were resected for CRLM (one patient with lung metastases). Clinical and treatment characteristics were similar in both arms. One-month postoperative complications were 39.3%/31.0% in arm A/B (p = 0.585). MPRR and complete PR were 32.1%/20.7% (p = 0.379)

Published
2022

39. Esophageal Melanocytosis: report of two cases and review of a rare and misunderstood entity.

Author

UCL - (SLuc) Service d'anatomie pathologique, Dubail, A, Dano, H, de Suray, N, Hassaini, H, Jouret-Mourin, A, UCL - (SLuc) Service d'anatomie pathologique, Dubail, A, Dano, H, de Suray, N, Hassaini, H, and Jouret-Mourin, A

Abstract

Esophageal melanocytosis (EM) is a rare entity, which is characterized by a non-atypical melanocytic proliferation and melanin deposits in the esophageal mucosa. The confusion between the terms of melanosis and melanocytosis in the literature, the rarity of this lesion (less than 50 cases reported in the literature), its uncertain pathobiological course and the lack of experience of pathologists and gastroenterologists prompt us to draw the attention to this particular entity by reporting two cases and reviewing the literature. Magnifying endoscopy to observe intensive melanin accumulation followed by a biopsy are key for the diagnosis.

Published
2022

40. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Service d'anatomie pathologique, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, Mlecnik, Bernhard, Torigoe, Toshihiko, Bindea, Gabriela, Popivanova, Boryana, Xu, Mingli, Fujita, Tomonobu, Hazama, Shoichi, Suzuki, Nobuaki, Nagano, Hiroaki, Okuno, Kiyotaka, Hirohashi, Yoshihiko, Furuhata, Tomohisa, Takemasa, Ichiro, Patel, Prabhudas, Vora, Hemangini, Shah, Birva, Patel, Jayendrakumar B, Rajvik, Kruti N, Pandya, Shashank J, Shukla, Shilin N, Wang, Yili, Zhang, Guanjun, Yoshino, Takayuki, Taniguchi, Hiroya, Bifulco, Carlo, Lugli, Alessandro, Lee, Jiun-Kae Jack, Zlobec, Inti, Rau, Tilman T, Berger, Martin D, Nagtegaal, Iris D, Vink-Börger, Elisa, Hartmann, Arndt, Geppert, Carol I, Kolwelter, Julie, Merkel, Susanne, Grützmann, Robert, Van den Eynde, Marc, Jouret-Mourin, Anne, Kartheuser, Alex, Léonard, Daniel, Remue, Christophe, Wang, Julia, Bavi, Prashant, Roehrl, Michael H A, Ohashi, Pamela S, Nguyen, Linh T, Han, SeongJun, MacGregor, Heather L, Hafezi-Bakhtiari, Sara, Wouters, Bradly G, Masucci, Giuseppe V, Andersson, Emilia, Zavadova, Eva, Vocka, Michal, Spacek, Jan, Petruzelka, Lubos, Konopasek, Bohuslav, Dundr, Pavel, Skalova, Helena, Nemejcova, Kristyna, Botti, Gerardo, Tatangelo, Fabiana, Delrio, Paolo, Ciliberto, Gennaro, Maio, Michele, Laghi, Luigi, Grizzi, Fabio, Marliot, Florence, Fredriksen, Tessa, Buttard, Bénédicte, Lafontaine, Lucie, Maby, Pauline, Majdi, Amine, Hijazi, Assia, El Sissy, Carine, Kirilovsky, Amos, Berger, Anne, Lagorce, Christine, Paustian, Christopher, Ballesteros-Merino, Carmen, Dijkstra, Jeroen, Van de Water, Carlijn, van Lent-van Vliet, Shannon, Knijn, Nikki, Mușină, Ana-Maria, Scripcariu, Dragos-Viorel, Marincola, Francesco M, Ascierto, Paolo A, Fox, Bernard A, Pagès, Franck, Kawakami, Yutaka, Galon, Jérôme, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Service d'anatomie pathologique, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, Mlecnik, Bernhard, Torigoe, Toshihiko, Bindea, Gabriela, Popivanova, Boryana, Xu, Mingli, Fujita, Tomonobu, Hazama, Shoichi, Suzuki, Nobuaki, Nagano, Hiroaki, Okuno, Kiyotaka, Hirohashi, Yoshihiko, Furuhata, Tomohisa, Takemasa, Ichiro, Patel, Prabhudas, Vora, Hemangini, Shah, Birva, Patel, Jayendrakumar B, Rajvik, Kruti N, Pandya, Shashank J, Shukla, Shilin N, Wang, Yili, Zhang, Guanjun, Yoshino, Takayuki, Taniguchi, Hiroya, Bifulco, Carlo, Lugli, Alessandro, Lee, Jiun-Kae Jack, Zlobec, Inti, Rau, Tilman T, Berger, Martin D, Nagtegaal, Iris D, Vink-Börger, Elisa, Hartmann, Arndt, Geppert, Carol I, Kolwelter, Julie, Merkel, Susanne, Grützmann, Robert, Van den Eynde, Marc, Jouret-Mourin, Anne, Kartheuser, Alex, Léonard, Daniel, Remue, Christophe, Wang, Julia, Bavi, Prashant, Roehrl, Michael H A, Ohashi, Pamela S, Nguyen, Linh T, Han, SeongJun, MacGregor, Heather L, Hafezi-Bakhtiari, Sara, Wouters, Bradly G, Masucci, Giuseppe V, Andersson, Emilia, Zavadova, Eva, Vocka, Michal, Spacek, Jan, Petruzelka, Lubos, Konopasek, Bohuslav, Dundr, Pavel, Skalova, Helena, Nemejcova, Kristyna, Botti, Gerardo, Tatangelo, Fabiana, Delrio, Paolo, Ciliberto, Gennaro, Maio, Michele, Laghi, Luigi, Grizzi, Fabio, Marliot, Florence, Fredriksen, Tessa, Buttard, Bénédicte, Lafontaine, Lucie, Maby, Pauline, Majdi, Amine, Hijazi, Assia, El Sissy, Carine, Kirilovsky, Amos, Berger, Anne, Lagorce, Christine, Paustian, Christopher, Ballesteros-Merino, Carmen, Dijkstra, Jeroen, Van de Water, Carlijn, van Lent-van Vliet, Shannon, Knijn, Nikki, Mușină, Ana-Maria, Scripcariu, Dragos-Viorel, Marincola, Francesco M, Ascierto, Paolo A, Fox, Bernard A, Pagès, Franck, Kawakami, Yutaka, and Galon, Jérôme

Abstract

In this study, we evaluated the prognostic value of Immunoscore in patients with stage I-III colon cancer (CC) in the Asian population. These patients were originally included in an international study led by the Society for Immunotherapy of Cancer (SITC) on 2681 patients with AJCC/UICC-TNM stages I-III CC. CD3+ and cytotoxic CD8+ T-lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The association of Immunoscore with prognosis was evaluated for time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS). Immunoscore stratified Asian patients (n = 423) into different risk categories and was not impacted by age. Recurrence-free rates at 3 years were 78.5%, 85.2%, and 98.3% for a Low, Intermediate, and High Immunoscore, respectively (HR[Low-vs-High] = 7.26 (95% CI 1.75-30.19); = 0.0064). A High Immunoscore showed a significant association with prolonged TTR, OS, and DFS ( < 0.05). In Cox multivariable analysis stratified by center, Immunoscore association with TTR was independent (HR[Low-vs-Int+High] = 2.22 (95% CI 1.10-4.55) = 0.0269) of the patient's gender, T-stage, N-stage, sidedness, and MSI status. A significant association of a High Immunoscore with prolonged TTR was also found among MSS (HR[Low-vs-Int+High] = 4.58 (95% CI 2.27-9.23); ≤ 0.0001), stage II (HR[Low-vs-Int+High] = 2.72 (95% CI 1.35-5.51); = 0.0052), low-risk stage-II (HR[Low-vs-Int+High] = 2.62 (95% CI 1.21-5.68); = 0.0146), and high-risk stage II patients (HR[Low-vs-Int+High] = 3.11 (95% CI 1.39-6.91); = 0.0055). A High Immunoscore is significantly associated with the prolonged survival of CC patients within the Asian population.

Published
2022

41. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study

Author

Mlecnik, B., Torigoe, T., Bindea, G., Popivanova, B., Xu, M., Fujita, T., Hazama, S., Suzuki, N., Nagano, H., Okuno, K., Hirohashi, Y., Furuhata, T., Takemasa, I., Patel, P., Vora, H., Shah, B., Patel, J.B., Rajvik, K.N., Pandya, S.J., Shukla, S.N., Wang, Yili, Zhang, G., Yoshino, T., Taniguchi, H., Bifulco, C., Lugli, A., Lee, J.J., Zlobec, I., Rau, T.T., Berger, M.D., Nagtegaal, I.D., Vink-Borger, Elisa, Hartmann, A., Geppert, C.I., Kolwelter, J., Merkel, S., Grützmann, R., Eynde, M. Van den, Jouret-Mourin, A., Kartheuser, A., Léonard, D., Remue, C., Wang, J., Bavi, P., Roehrl, M.H.A., Ohashi, P.S., Nguyen, L.T., Han, S., MacGregor, H.L., Hafezi-Bakhtiari, S., Wouters, B.G., Masucci, G.V., Andersson, E., Zavadova, E., Vocka, M., Spacek, J., Petruzelka, L., Konopasek, B., Dundr, P., Skalova, H., Nemejcova, K., Botti, G., Tatangelo, F., Delrio, P., Ciliberto, G., Maio, M, Laghi, L., Grizzi, F., Marliot, F., Fredriksen, T., Buttard, B., Lafontaine, L., Maby, P., Majdi, A., Hijazi, A., Sissy, C. El, Kirilovsky, A., Berger, A., Lagorce, C., Paustian, C., Ballesteros-Merino, C., Dijkstra, J.R., Water, C. van de, Lent-van Vliet, S. van, Knijn, N., Mușină, A.M., Scripcariu, D.V., Marincola, F.M., Ascierto, P.A., Fox, B.A., Pagès, F., Kawakami, Y., Galon, J., Mlecnik, B., Torigoe, T., Bindea, G., Popivanova, B., Xu, M., Fujita, T., Hazama, S., Suzuki, N., Nagano, H., Okuno, K., Hirohashi, Y., Furuhata, T., Takemasa, I., Patel, P., Vora, H., Shah, B., Patel, J.B., Rajvik, K.N., Pandya, S.J., Shukla, S.N., Wang, Yili, Zhang, G., Yoshino, T., Taniguchi, H., Bifulco, C., Lugli, A., Lee, J.J., Zlobec, I., Rau, T.T., Berger, M.D., Nagtegaal, I.D., Vink-Borger, Elisa, Hartmann, A., Geppert, C.I., Kolwelter, J., Merkel, S., Grützmann, R., Eynde, M. Van den, Jouret-Mourin, A., Kartheuser, A., Léonard, D., Remue, C., Wang, J., Bavi, P., Roehrl, M.H.A., Ohashi, P.S., Nguyen, L.T., Han, S., MacGregor, H.L., Hafezi-Bakhtiari, S., Wouters, B.G., Masucci, G.V., Andersson, E., Zavadova, E., Vocka, M., Spacek, J., Petruzelka, L., Konopasek, B., Dundr, P., Skalova, H., Nemejcova, K., Botti, G., Tatangelo, F., Delrio, P., Ciliberto, G., Maio, M, Laghi, L., Grizzi, F., Marliot, F., Fredriksen, T., Buttard, B., Lafontaine, L., Maby, P., Majdi, A., Hijazi, A., Sissy, C. El, Kirilovsky, A., Berger, A., Lagorce, C., Paustian, C., Ballesteros-Merino, C., Dijkstra, J.R., Water, C. van de, Lent-van Vliet, S. van, Knijn, N., Mușină, A.M., Scripcariu, D.V., Marincola, F.M., Ascierto, P.A., Fox, B.A., Pagès, F., Kawakami, Y., and Galon, J.

Abstract

Contains fulltext : 283495.pdf (Publisher’s version ) (Open Access), BACKGROUND: In this study, we evaluated the prognostic value of Immunoscore in patients with stage I-III colon cancer (CC) in the Asian population. These patients were originally included in an international study led by the Society for Immunotherapy of Cancer (SITC) on 2681 patients with AJCC/UICC-TNM stages I-III CC. METHODS: CD3+ and cytotoxic CD8+ T-lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The association of Immunoscore with prognosis was evaluated for time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS). RESULTS: Immunoscore stratified Asian patients (n = 423) into different risk categories and was not impacted by age. Recurrence-free rates at 3 years were 78.5%, 85.2%, and 98.3% for a Low, Intermediate, and High Immunoscore, respectively (HR[Low-vs-High] = 7.26 (95% CI 1.75-30.19); p = 0.0064). A High Immunoscore showed a significant association with prolonged TTR, OS, and DFS (p < 0.05). In Cox multivariable analysis stratified by center, Immunoscore association with TTR was independent (HR[Low-vs-Int+High] = 2.22 (95% CI 1.10-4.55) p = 0.0269) of the patient's gender, T-stage, N-stage, sidedness, and MSI status. A significant association of a High Immunoscore with prolonged TTR was also found among MSS (HR[Low-vs-Int+High] = 4.58 (95% CI 2.27-9.23); p ≤ 0.0001), stage II (HR[Low-vs-Int+High] = 2.72 (95% CI 1.35-5.51); p = 0.0052), low-risk stage-II (HR[Low-vs-Int+High] = 2.62 (95% CI 1.21-5.68); p = 0.0146), and high-risk stage II patients (HR[Low-vs-Int+High] = 3.11 (95% CI 1.39-6.91); p = 0.0055). CONCLUSION: A High Immunoscore is significantly associated with the prolonged survival of CC patients within the Asian population.

Published
2022

43. Esophageal Melanocytosis: report of two cases and review of a rare and misunderstood entity

Author

A, Dubail, H, Dano, N, de Suray, H, Hassaini, A, Jouret-Mourin, and UCL - (SLuc) Service d'anatomie pathologique

Subjects
Melanins, esophagus, Esophagus, Esophageal Mucosa, Biopsy, melanocytosis, Humans, melanocytic lesion, melanosis, pseudomelanosis, Melanosis
Abstract

Esophageal melanocytosis (EM) is a rare entity, which is characterized by a non-atypical melanocytic proliferation and melanin deposits in the esophageal mucosa. The confusion between the terms of melanosis and melanocytosis in the literature, the rarity of this lesion (less than 50 cases reported in the literature), its uncertain pathobiological course and the lack of experience of pathologists and gastroenterologists prompt us to draw the attention to this particular entity by reporting two cases and reviewing the literature. Magnifying endoscopy to observe intensive melanin accumulation followed by a biopsy are key for the diagnosis.

Published
2022

44. Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)

Author

Pamela Baldin, Javier Carrasco, Gabriela Beniuga, Anne Jouret-Mourin, Gauthier Demolin, Sandrine Roland, Lionel D’Hondt, Philippe Vergauwe, Daniel Van Daele, Marie Mailleux, Isabelle Sinapi, Astrid De Cuyper, Noëlla Blétard, Brigitte Massart, Monique Delos, Marie-Laure Castella, Aline van Maanen, Marc Van den Eynde, UCL - (MGD) Service d'anatomie pathologique, UCL - (MGD) Service d'oncologie médicale, UCL - SSS/IREC/MORF - Pôle de Morphologie, and UCL - SSS/IREC/MONT - Pôle Mont Godinne

Subjects
Cancer Research, Oncology, bevacizumab, chemotherapy, colorectal liver metastases, pathological response, histological growth pattern, tumoral homogeneity
Abstract

Retrospective studies reported that preoperative oxaliplatin-based chemotherapy increased pathological response (PR) in patients resected for colorectal liver metastases (CRLM). This multicenter prospective randomized (1/1) phase II trial evaluated PR on resected CRLM after preoperative mFOLFOX6 (arm A) or FOLFIRI (arm B) + bevacizumab. The primary endpoint was the major pathological response rate (MPRR), defined as the percentage of patients presenting CRLMs with mean tumor regression grade (TRG) < 3. Secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). Out of 65 patients, 57 patients (28 and 29 in arm A/B) were resected for CRLM (one patient with lung metastases). Clinical and treatment characteristics were similar in both arms. One-month postoperative complications were 39.3%/31.0% in arm A/B (p = 0.585). MPRR and complete PR were 32.1%/20.7% (p = 0.379) and 14.3%/0.0% (p = 0.052) in arm A/B, respectively. PFS and OS were not different. Patients with PR among all CRLMs (max TRG ≤ 3; 43.8% of patients) had a lower risk of relapse (PFS: HR = 0.41, 95%CI = 0.204–0.840, p = 0.015) and a tendency towards better survival (OS: HR = 0.34, 95%CI = 0.104–1.114, p = 0.075). The homogeneity of PR was associated with improved PFS/OS. This trial fails to demonstrate a significant increase in MPRR in patients treated with mFOLFOX6-bevacizumab but confirms PR as an important prognostic factor.

Published
2021

48. Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)

Author

Baldin, Pamela, primary, Carrasco, Javier, additional, Beniuga, Gabriela, additional, Jouret-Mourin, Anne, additional, Demolin, Gauthier, additional, Roland, Sandrine, additional, D’Hondt, Lionel, additional, Vergauwe, Philippe, additional, Van Daele, Daniel Van, additional, Mailleux, Marie, additional, Sinapi, Isabelle, additional, De Cuyper, Astrid De, additional, Blétard, Noëlla, additional, Massart, Brigitte, additional, Delos, Monique, additional, Castella, Marie-Laure, additional, van Maanen, Aline van, additional, and Van den Eynde, Marc Van den, additional

Published
2022
Full Text
View/download PDF

50. Un cas inhabituel d’entéropathie secondaire à la prise d’olmesartan

Author

Hélène Dano, Paulina Henry, Anne Jouret-Mourin, and Hubert Piessevaux

Subjects
0301 basic medicine, medicine.medical_specialty, Lamina propria, Gastrointestinal tract, business.industry, medicine.disease, Gastroenterology, Pathology and Forensic Medicine, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Internal medicine, medicine, Duodenum, Intraepithelial lymphocyte, Enteropathy, Villous atrophy, business, Olmesartan, Adverse effect, medicine.drug
Abstract

Olmesartan induced enteropathy was first described in 2012. It is a rare adverse effect of this antihypertensive drug. The clinical presentation commonly includes severe chronic diarrhea leading to weight loss and a variable degree of dehydration. Histological findings are most commonly observed in the duodenum and consist of partial or total villous atrophy, increased intraepithelial lymphocytes and inflammation in the lamina propria. Involvement of gastric and colic mucosa has also been described. We report on the case of a 63-year-old man, treated by olmesartan, who presented with severe chronic diarrhea. Biopsies from different levels of the gastrointestinal tract revealed a pandigestive intraepithelial lymphocytosis.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results